Recombinant Full Length Human Apolipoprotein L Domain-Containing Protein 1(Apold1) Protein, His-Tagged

• Cat.No.: RFL4776HF
• Product Overview: Recombinant Full Length Human Apolipoprotein L domain-containing protein 1(APOLD1) Protein (Q96LR9) (1-279aa), fused to N-terminal His tag, was expressed in E. coli.

Specification

• Source: E.coli expression system
• Species: Homo sapiens (Human)
• Tag: His
• Form: Lyophilized powder
• Protein Length: Full Length (1-279aa)
• AA Sequence: MFRAPCHRLRARGTRKARAGAWRGC TFPCLGKGMERPAAREPHGPDALRR FQGLLLDRRGRLHGQVLRLREVARR LERLRRRSLVANVAGSSLSATGALA AIVGLSLSPVTLGTSLLVSAVGLGV ATAGGAVTITSDLSLIFCNSRELRR VQEIAATCQDQMREILSCLEFFCRW QGCGDRQLLQCGRNASIALYNSVYF IVFFGSRGFLIPRRAEGDTKVSQAV LKAKIQKLAESLESCTGALDELSEQ LESRVQLCTKSSRGHDLKISADQRA GLFF Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
• Purity: Greater than 90% as determined by SDS-PAGE.
• Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Tris/PBS-based buffer, 6% Trehalose, pH 8.0
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
• Gene Name: APOLD1
• Synonyms: APOLD1; VERGE; Apolipoprotein L domain-containing protein 1; Vascular early response gene protein
• UniProt ID: Q96LR9

Gene Information

• Gene Name: APOLD1
• Synonyms: APOLD1; VERGE; Apolipoprotein L domain-containing protein 1; Vascular early response gene protein
• UniProt ID: Q96LR9

Reviews

03/05/2021

I am confident that my experimental needs will be met through their assistance, ensuring successful outcomes in my trials.

06/26/2020

the manufacturer's commitment to delivering the APOLD1 protein in a timely manner is greatly appreciated.

02/15/2020

The cost-effectiveness of the APOLD1 protein, competitive pricing, and the availability of bulk purchase options provided by the manufacturer also align with my budget considerations, allowing me to optimize my resources.

11/21/2016

Their prompt and knowledgeable assistance has the potential to solve any difficulties I may encounter during my experiments.

Q&As

Are there any animal models available for studying APOLD1?

At present, there are no known APOLD1-specific animal models. However, researchers may utilize knockout or knockdown approaches to investigate the effects of APOLD1 manipulation in animal studies.

Can APOLD1 expression be influenced by hormones or cellular signals?

There is limited information on the regulation of APOLD1 expression by hormones or cellular signals. However, some studies have suggested potential modulation of APOLD1 expression by insulin and glucagon, which are key regulators of lipid metabolism. Further research is needed to understand the precise mechanisms regulating APOLD1 expression.

Are there any known interacting partners of APOLD1?

There is limited information available regarding the specific interacting partners of APOLD1. However, it has been suggested to interact with other proteins involved in lipid metabolism, such as lipases and lipid transporters.

Are there any inhibitors or activators of APOLD1?

Currently, there are no known specific inhibitors or activators of APOLD1. Since the exact functions and mechanisms of APOLD1 are not fully understood, the development of small molecule inhibitors or activators targeting this protein has been challenging. Further research is needed to identify potential compounds that can selectively modulate APOLD1 activity.

Does APOLD1 have any roles in cellular processes other than lipid metabolism?

While APOLD1's primary role is believed to be related to lipid metabolism, its exact functions and potential involvement in other cellular processes are still being investigated. Further research is needed to fully understand its broader role, if any, beyond lipid metabolism.

Can APOLD1 levels be influenced by external factors or environmental conditions?

The regulation of APOLD1 expression by external factors or environmental conditions is not well established. However, certain nutritional factors and hormones, such as dietary lipids or insulin, may potentially influence the expression or activity of APOLD1.

What are the structural features of APOLD1?

APOLD1 contains an N-terminal apolipoprotein L domain, which is a conserved structural domain found in the apolipoprotein L family of proteins. It also contains a C-terminal transmembrane domain, suggesting its association with cellular membranes.

Are there any animal models or knockout studies for APOLD1?

As of now, there are no specific animal models or knockout studies for APOLD1. However, some studies have used cell culture models and genetic association studies in human populations to explore the role of APOLD1 in different aspects of lipid metabolism and related diseases. Animal models, particularly knockout mice, could provide further insights into understanding the function and potential therapeutic implications of APOLD1.

How is the expression of APOLD1 regulated?

The regulation of APOLD1 expression is not well understood. However, studies have suggested that certain transcription factors and hormones, such as peroxisome proliferator-activated receptors (PPARs), may be involved in its regulation.

Are there any known interactions between APOLD1 and other proteins or molecules?

There is limited information available on specific protein-protein interactions involving APOLD1. However, some studies have suggested potential interactions with proteins involved in lipid metabolism, such as perilipins and members of the PAT (perilipin, ADRP, and TIP47) family. Further research is needed to determine the full extent of APOLD1 interactions.

Has APOLD1 been associated with any diseases or health conditions?

APOLD1 has been implicated in various metabolic disorders and conditions related to lipid metabolism. Genome-wide association studies have identified APOLD1 gene variants associated with traits such as blood lipid levels, body mass index, and obesity. Additionally, altered APOLD1 expression has been observed in certain diseases, including nonalcoholic fatty liver disease (NAFLD) and atherosclerosis, suggesting potential roles in these pathologies.

Are there any known genetic variations or mutations associated with APOLD1?

Currently, there is limited information available on specific genetic variations or mutations in the APOLD1 gene. However, genome-wide association studies (GWAS) have identified APOLD1 gene variants that may be associated with lipid-related traits and metabolic disorders in certain populations.

Is APOLD1 expression tissue-specific?

APOLD1 expression has been reported in various tissues, including adipose tissue, liver, heart, and skeletal muscle. However, the expression levels of APOLD1 may vary between tissues, suggesting potential tissue-specific regulation. Further studies are required to elucidate the tissue distribution and regulation of APOLD1 expression.

Can APOLD1 expression be modified by lifestyle factors such as diet and exercise?

Although research on the specific effects of lifestyle factors on APOLD1 expression is limited, it is plausible that lifestyle factors, such as diet and exercise, could influence APOLD1 expression. Lifestyle interventions have been shown to modulate gene expression related to metabolism and lipid metabolism. Therefore, further investigations are needed to determine the impact of diet and exercise on APOLD1 expression and its potential role in mediating the effects of lifestyle factors on lipid metabolism.

Is APOLD1 associated with any diseases?

There is currently limited information on the involvement of APOLD1 in diseases. However, some studies have suggested potential associations between APOLD1 gene variants and metabolic disorders, such as obesity and dyslipidemia.

Which cellular compartments or organelles are APOLD1 localized in?

APOLD1 has been observed to predominantly localize in the endoplasmic reticulum (ER) and lipid droplets within cells.

Can APOLD1 be used as a diagnostic marker for any diseases?

While APOLD1 has been associated with certain metabolic disorders and lipid metabolism-related conditions, it is not currently used as a diagnostic marker for any specific disease. The exact diagnostic potential of APOLD1 needs to be further evaluated, including assessing its sensitivity, specificity, and predictive value. Additional studies are necessary to determine if APOLD1 could serve as a diagnostic marker in clinical practice.

Are there any ongoing clinical trials targeting APOLD1?

At this time, there are no ongoing clinical trials specifically targeting APOLD1. However, given the emerging role of APOLD1 in lipid metabolism and its potential relevance to metabolic disorders, future research may explore therapeutic interventions targeting APOLD1. Engaging in clinical trials will provide a better understanding of APOLD1's therapeutic potential and its impact on disease progression.

Is APOLD1 involved in any physiological processes aside from metabolism?

While APOLD1's primary function is believed to be related to lipid metabolism, there is limited information on its involvement in other physiological processes. However, some studies suggest potential roles in inflammation, oxidative stress, and cellular responses to stress conditions.

Does APOLD1 have any therapeutic implications?

APOLD1's potential as a therapeutic target or its role in disease progression is not yet fully understood. However, given its association with metabolic disorders and lipid metabolism, further research on APOLD1 may shed light on its therapeutic potential in managing these conditions. Developing a deeper understanding of the molecular mechanisms involving APOLD1 could lead to novel strategies for intervention and treatment.